Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Acute Myeloid Leukemia with t(6;9)(p23;q34) Is Associated Poor Outcome in Childhood AML Regardless of FLT3/ITD Status, A Report From Children's Oncology Group.

Pilar Palomo Moraleda, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Yaddanapudi Ravindranath, MD, Beverly Lange, MD, William G. Woods, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 2541.

https://doi.org/10.1182/blood.V120.21.2541.2541

Published: 2012

Journal Articles

A New Case of KLF1 G973A Mutation and Congenital Dyserythropoeitic Anemia (CDA)- Further Definition of Emerging New Syndrome and Possible Association with Gonadal Dysgenesis

Yaddanapudi Ravindranath, MD, Gerald Goyette, BS, Steven Buck, MS, Manisha Gadgeel, MD, Alan Dombkowski, Ph.D, Laurence A. Boxer, MD, Patrick G. Gallagher, MD, Robert M Johnson, Ph.D

Blood (2011) 118 (21): 2101.

https://doi.org/10.1182/blood.V118.21.2101.2101

Published: 2011

Journal Articles

Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421

Norman J. Lacayo, MD, Aileen Cohen, Ph.D., M.D., Matt Westfall, Ph.D., Alan Lackey, MS, Xiaohua (Robert) Xin, Ph.D., M.D., Urte Gayko, Ph.D., Santosh Putta, Ph.D., Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Todd A. Alonzo, PhD, Robert J. Arceci, MD, PhD, Yaddanapudi Ravindranath, MD, Gary Van Houten Dahl, MD, Alessandra Cesano, MD

Blood (2010) 116 (21): 954.

https://doi.org/10.1182/blood.V116.21.954.954

Published: 2010

Journal Articles

Tumor Microenvironment In Pediatric Hodgkin Lymphoma: Clues for Disease Biology

Meret Henry, MD, Janet Poulik, MD, Steven Buck, Yaddanapudi Ravindranath, MD, Sureyya Savasan, MD

Blood (2010) 116 (21): 2681.

https://doi.org/10.1182/blood.V116.21.2681.2681

Published: 2010

Journal Articles

Enhanced Elimination of 6-Mercaptopurine or Methotrexate-Treated Acute Lymphoblastic Leukemia Cells by Natural Killer Lymphocytes In Vitro: A Potential Mechanism of Action of Maintenance Chemotherapy

Abdual H. Siddiqui, MBBS, MD, Mohammad Bhuiyan, MD, PhD, Akila Muthukumar, MD, Steven Buck, Yaddanapudi Ravindranath, MD, Sureyya Savasan, MD

Blood (2010) 116 (21): 2128.

https://doi.org/10.1182/blood.V116.21.2128.2128

Published: 2010

Journal Articles

Excessive Cardiotoxicity Despite Excellent Leukemia-Free Survival for Pediatric Patients with Down Syndrome (DS) and Acute Myeloid Leukemia (AML): Results from POG (Pediatric Oncology Group) Protocol 9421.

Maureen O’Brien, MD, Jeffrey Taub, MD, Kimo Stine, MD, Myron Chang, Yaddanapudi Ravindranath, MD, David Becton, MD, Gary Van Houten Dahl, MD

Blood (2006) 108 (11): 559.

https://doi.org/10.1182/blood.V108.11.559.559

Published: 2006

Journal Articles

TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group).

Kimo Stine, MD, David Becton, MD, Gary Van Houten Dahl, MD, Yaddanapudi Ravindranath, MD, Susana C. Raimondi, PhD, Fred Behm, MD, Myron Chang, Robert Arceci, MD

Blood (2006) 108 (11): 3677.

https://doi.org/10.1182/blood.V108.11.3677.3677

Published: 2006

Journal Articles

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman J. Lacayo, MD, Maureen O’Brien, MD, Shweta Jain, Soheil Meshinchi, MD, PhD, Ron Yu, PhD, Dejan Juric, MD, Myron N. Chang, PhD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Howard J. Weinstein, MD, Branimir I. Sikic, MD, Gary Van Houten Dahl, MD

Blood (2006) 108 (11): 1915.

https://doi.org/10.1182/blood.V108.11.1915.1915

Published: 2006

Journal Articles

Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971.

Alan S. Gamis, MD, Todd A. Alonzo, PhD, Joanne M. Hilden, MD, Robert B. Gerbing, MA, Thomas W. Loew, MD, Lois Hathaway, CCRP, Loris McGavran, PhD, Dorothy Barnard, MD, Jeffrey W. Taub, MD, Yaddanapudi Ravindranath, MD, Franklin O. Smith, MD, Robert Arceci, MD, PhD

Blood (2006) 108 (11): 15.

https://doi.org/10.1182/blood.V108.11.15.15

Published: 2006

Journal Articles

A Prospective Study of G-CSF Primed Bone Marrow from Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study.

Haydar Frangoul, MD, Ann Woolfrey, MD, Shakila Khan, MD, Michael Pulsipher, MD, John Levine, MD, David Baker, MD, Mark Walters, MD, Mouhab Ayas, MD, Yaddanapudi Ravindranath, MD, Stephan Grupp, MD, PhD, Dean Billheimer, PhD, Eneida Nemecek, MD

Blood (2005) 106 (11): 1964.

https://doi.org/10.1182/blood.V106.11.1964.1964

Published: 2005

Journal Articles

Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial.

Jeffrey Rubnitz, MD, PhD, Bassem Razzouk, MD, Paul Bowman, MD, Gary Dahl, MD, Norman Lacayo, MD, Jeffrey Taub, MD, Yaddanapudi Ravindranath, MD, Soheil Meshinchi, MD, PhD, Gladstone Airewele, MD, Shelly Lensing, MS, Stanley Pounds, PhD, Raul Ribeiro, MD, Ching-Hon Pui, MD, Elaine Coustan-Smith, MS, Dario Campana, MD

Blood (2005) 106 (11): 275.

https://doi.org/10.1182/blood.V106.11.275.275

Published: 2005

Journal Articles

Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421.

Dennis J. Kuo, MD, Norman J. Lacayo, MD, Don Hoang, Dejan Juric, MD, Susana C. Raimondi, PhD, David Chen, Myron N. Chang, PhD, Yaddanapudi Ravindranath, MD, Howard J. Weinstein, MD, Branimir I. Sikic, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2771.

https://doi.org/10.1182/blood.V106.11.2771.2771

Published: 2005

Journal Articles

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman Lacayo, MD, Soheil Meshinchi, MD, Susana Raimondi, PhD, Chitra Saraiya, MS, Maureen O’Brien, MD, Ronald Yu, PhD, Dejan Juric, MD, Myron Chang, PhD, Cheryl Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir Sikic, MD, Howard Weinstein, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2372.

https://doi.org/10.1182/blood.V106.11.2372.2372

Published: 2005

Journal Articles

Outcome of Children with Hyperdiploid Acute Lymphoblastic Leukemia- an Apparent Predisposition for Extramedullary Relapse and High Salvage Rate. A Single Institution Experience.

Anjali Sharathkumar, MD, Mehul Patel, Ronald Thomas, PhD, Yaddanapudi Ravindranath, MD, Jeffrey W. Taub, MD

Blood (2004) 104 (11): 1956.

https://doi.org/10.1182/blood.V104.11.1956.1956

Published: 2004

Journal Articles

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

Dennis J. Kuo, MD, Norman J. Lacayo, MD, Steven Buck, MS, Ron Yu, MA, Chitra Saraiya, MS, Lorrie Douglas, BS, Howard Weinstein, MD, Myron Chang, MD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Gary V. Dahl, MD, Branimir Sikic, MD, Yaddanapudi Ravindranath, MD

Blood (2004) 104 (11): 1130.

https://doi.org/10.1182/blood.V104.11.1130.1130

Published: 2004

Journal Articles

Endothelial Cell Injury of Carmustine (BCNU) in Hepatic Sinusoids: Contribution of Oxidation and Immune Reaction.

Oner Ozdemir, MD, Yaddanapudi Ravindranath, MD, Sureyya Savasan, MD

Blood (2004) 104 (11): 1154.

https://doi.org/10.1182/blood.V104.11.1154.1154

Published: 2004

Journal Articles

Aerolysin Cytotoxicity Can Serve as a Surrogate Marker for Immune Sensitivity of Tumor Cells to Granule-Exocytosis Pathway in Vitro.

Oner Ozdemir, MD, Mustafa Buyukavci, MD, Yaddanapudi Ravindranath, MD, Sureyya Savasan, MD

Blood (2004) 104 (11): 3864.

https://doi.org/10.1182/blood.V104.11.3864.3864

Published: 2004

Journal Articles

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Norman J. Lacayo, MD, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Dennis J. Kuo, MD, Ron Yu, MA, Myron N. Chang, PhD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir I. Sikic, MD, Howard Weinstein, MD, Gary V. Dahl, MD

Blood (2004) 104 (11): 570.

https://doi.org/10.1182/blood.V104.11.570.570

Published: 2004

Journal Articles

Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).

Kimo Stine, MD, David Becton, MD, Gary Van Houten Dahl, MD, Yaddanapudi Ravindranath, MD, Susana C. Raimondi, PhD, Fred G. Behm, MD, Myron Chang, PhD, Howard Weinstein, MD

Blood (2004) 104 (11): 616.

https://doi.org/10.1182/blood.V104.11.616.616

Published: 2004

NARROW

Acute Myeloid Leukemia with t(6;9)(p23;q34) Is Associated Poor Outcome in Childhood AML Regardless of FLT3/ITD Status, A Report From Children's Oncology Group.

A New Case of KLF1 G973A Mutation and Congenital Dyserythropoeitic Anemia (CDA)- Further Definition of Emerging New Syndrome and Possible Association with Gonadal Dysgenesis

Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421

Tumor Microenvironment In Pediatric Hodgkin Lymphoma: Clues for Disease Biology

Enhanced Elimination of 6-Mercaptopurine or Methotrexate-Treated Acute Lymphoblastic Leukemia Cells by Natural Killer Lymphocytes In Vitro: A Potential Mechanism of Action of Maintenance Chemotherapy

Excessive Cardiotoxicity Despite Excellent Leukemia-Free Survival for Pediatric Patients with Down Syndrome (DS) and Acute Myeloid Leukemia (AML): Results from POG (Pediatric Oncology Group) Protocol 9421.

TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group).

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971.

A Prospective Study of G-CSF Primed Bone Marrow from Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study.

Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial.

Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421.

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Outcome of Children with Hyperdiploid Acute Lymphoblastic Leukemia- an Apparent Predisposition for Extramedullary Relapse and High Salvage Rate. A Single Institution Experience.

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

Endothelial Cell Injury of Carmustine (BCNU) in Hepatic Sinusoids: Contribution of Oxidation and Immune Reaction.

Aerolysin Cytotoxicity Can Serve as a Surrogate Marker for Immune Sensitivity of Tumor Cells to Granule-Exocytosis Pathway in Vitro.

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only